Female Sexual Dysfunction: Lead Agents Are New Formulations Of Marketed Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Procter & Gamble will likely have the first product to treat hypoactive sexual desire disorder in women with its Phase III testosterone patch Intrinsa. Vivus has late-stage compounds for two major components of female sexual dysfunction: a testosterone spray for hypoactive desire and a topical alprostadil for female sexual arousal disorder.
You may also be interested in...
P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005
NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.
P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005
NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.
BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
Company aims to capture 10%-20% of the testosterone gel market with Bio-T-Gel. Female sexual dysfunction will be next frontier for BioSante gels, with Procter & Gamble as trailblazer in FSD market, BioSante CEO says.